|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nonalclholic fatty liver disease:a spectram of clinical and pathological serverity显示文摘 | Matteoni C A Younossi Z M Gramlich T | 1999 | Gastroenterolo gy1999，116，6： | 1 |
| 2 | Acute pancreatitis: practical consid-erations in nutrition support 显示文摘 | Gramlich L Taft A K | 2007 | Curr Gastroenterol Rep2007，9，4： | 1 |
| 3 | TLR2-activated human langerhans cells promote Th17 polarization via IL-1beta,TGF-beta and IL-23显示文摘 | Aliahmadi E Gramlich R Grützkau A | | 0，，05： | 1 |
| 4 | TLR2-activated human langerhans cells promote Th 17 polarization via IL-1 beta,TGF-beta and IL-23显示文摘 | ALIAHMADI E GRAMLICH R GRUTZKAU A HITZLER M KRUGER M'BAUMGRASS R e al | 2009 | Eur J Immunol2009，39，5： | 1 |
| 5 | Nonalcoholic fatty liver disease in patients with type 2 diabetes显示文摘 | YOUNOSSI Z M GRAMLICH T MATrEONI C A | 2004 | Clin Gastroenterol Hepatol2004，2，3： | 1 |
| 6 | Pathologic features associated with fibrosis in nonalcoholic fatty liver disease显示文摘 | Gramlich T Kleiner DE Mccullough A J | 2004 | Hum Pathol2004，35，2： | 1 |
| 7 | Pathologic features associated with fibrosis in nonalcoholic fatty liver disease显示文摘 | GRAMLICH T KLEINER D E MCCULLOUGH A J | 2004 | Hum Pathol2004，35，2： | 1 |
| 8 | TLR2- activated human langerhans cells promote Thl7 polarization via IL-lbeta, TGF-beta and IL-23 显示文摘 | Aliahmadi E Gramlich R Grtitzkau A | 2007 | J Immunol2007，178，4： | 1 |
| 9 | Nonalcoholic fatty liver disease in patients with type 2diabetes显示文摘 | Younossi Z M Gramlich T Matreoni C A | 2004 | Clin Gastroenterol Hepatol2004，2，3： | 1 |
| 10 | Nonal- coholic fatty liver disease: a spectrum of clinical and path- ological severity显示文摘 | Matteoni C A Younossi Z M Gramlich T | 1999 | Gastroenterology1999，116，6： | 1 |
| 11 | p53 expression in low grade dysplasia in Barrett’s esophagus: correlation with interobserver agreement and disease progression显示文摘 | Marek Skacel Robert E Petras Lisa A Rybicki Terry L Gramlich Joel E Richter Gary W Falk John R Goldblum | 2002 | The American Journal of Gastroenterology2002，，10： | 1 |
| 12 | Availability of zinc and the lig-ands citrate and histidine to wheat:Does uptake of entire complexesplay a role?显示文摘 | Gramlich A Tandy S Frossaxd E | 2013 | Journal of Agricultural and Food Chemistry2013，61，10： | 1 |
| 13 | Nonalcoholic fatty liver disease:a spectrum of clinical and pathological severity显示文摘 | MATTEONI C A YOUNOSSI Z M GRAMLICH T | 1999 | Gastroenterology1999，116，6： | 1 |
| 14 | Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation显示文摘AIM:To investigate genetic differences between Crohn's disease(CD) patients with a sustained remission vs relapsers after discontinuing infliximab while in corticosteroid-free remission.METHODS:Forty-eight CD patients received infliximab and were in full corticosteroid-free clinical remission but then discontinued infliximab for reasons other than a loss of response,were identified by review of an electronic database and charts.Infliximab-associated remission was defined as corticosteroid-free plus normalization of clinical disease activity [CD activity index(CDAI) < 150] during follow-up visits based on physician global assessments.A CD relapse(loss of infliximab-induced remission) was clinically defined as a physician visit for symptoms of disease activity(CDAI > 220) and a therapeutic intervention with CD medication(s),or a hospitalization with complications related to active CD.Genetic analyses were performed on samples from 14 patients(n = 6 who had a sustained long term remission after stopping infliximab,n = 8 who rapidly relapsed after stopping infliximab).Nucleotide-binding oligomerization domain 2(NOD2)/caspase activation recruitment domain 15(CARD15) polymorphisms(R702W,G908R and L1007fs) and the inflammatory bowel disease 5(IBD5) polymorphisms(IGR2060a1 and IGR3081a1) were analyzed in each group.RESULTS:Five single nucleotide polymorphisms of IBD5 and NOD2/CARD15 genes were successfully analyzed for all 14 subjects.There was no significant increase in frequency of the NOD2/CARD15 polymorphisms(R702W,G908R and L1007fs) and the IBD5 polymorphisms(IGR2060a1 and IGR3081a1) in either group of patients;those whose disease relapsed rapidly or those who remained in sustained long term remission following the discontinuation of infliximab.Nearly a third of patients in full clinical remission who stopped infliximab for reasons other than loss of response remained in sustained clinical remission,while two-thirds relapsed rapidly.There was a marked difference in the duration of clinical remission following discontinuance of infliximab between the two groups.The patients who lost remission did so after 1.0 years ± 0.6 years,while those still in remission were at the time of this study,8.1 years ± 2.6 years post-discontinuation of infliximab,P < 0.001.The 8 patients who had lost remission after discontinuing infliximab had a mean number of 5 infusions(range 3-7),with a mean treatment time of 7.2 mo(range 1.5 mo-15 mo).The mean duration of time from the last infusion of infliximab to the time of loss of remission was 382 d(range 20 d-701 d).The 6 patients who remained in remission after discontinuing infliximab had a mean number of 6 infusions(range 3-12),with a mean treatment duration of 12 mo(range 3.6 mo-32 mo)(P = 0.45 relative to those who lost remission).CONCLUSION:There are no IBD5 or NOD2/CARD15 mutations that predict which patients might have sustained remission and which will relapse rapidly after stopping infliximab. | Cathy Lu Alistair Waugh Robert J Bailey Raeleen Cherry Levinus A Dieleman Leah Gramlich Kata Matic Mario Millan Karen I Kroeker Daniel Sadowski Christopher W Teshima Dennis Todoruk Clarence Wong Karen Wong Richard N Fedorak | 2012 | World Journal of Gastroenterology2012，18，36： | 1 |
| 15 | Nonalco-holic fatty liver disease: A spectrum of clinical and patho-logical severity显示文摘 | Matteoni C A Younossi Z M Gramlich T | 1999 | Gastroenterology1999，116，6： | 1 |
| 16 | Nonalcoholic Fatty Liver Disease: a Spectrum of Clinical and Pathological Severity显示文摘 | Matteoni C A Younossi Z M Gramlich T | 1999 | Astroenterology1999，116，6： | 1 |
| 17 | Cytokeratin subsets can reliably distinguish Barrett' s esophelgus from intestinal metaplasia of the stomach显示文摘 | Ormsby A H Goldblum J R Rice T W Richter J E Falk G W Vaezi M F Gramlich T L | 1999 | Hum Pathol1999，30，： | 1 |
| 18 | Five New Cobalt(Ⅱ) and Copper(Ⅱ)-1,2,4,5-benzenetetracarboxylate Supramolecular Architectures Syntheses, Structures, and Magnetic, Properties显示文摘 | Majumder A Gramlich V Rosair G M | 2002 | Crystal Growth& Design2002，2，5： | 1 |
| 19 | Nonalcoholic fatty liver disease: aspectrum of clinical and pathological severity显示文摘 | Matteoni C A Younossi Z M Gramlich T Boparai N Liu Y C McCullough A J | 1999 | Gastroenterology1999，116，： | 1 |
| 20 | Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity 显示文摘 | Matteoni C A Younossi Z Gramlich T | 1999 | Gastroenterology1999，116，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员